Innovative Pipeline


Glenmark’s innovative pipeline is focused on three core therapeutic areas: oncology, dermatology and respiratory. With more than 350 scientists dedicated to new chemical entity (NCE) research and more than 100 scientists involved in new biologic entity (NBE) research, we have developed an enviable and robust pipeline anchored in first- and best-in-class discovery. With seven investigational drugs in various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.

Click here to view our full pipeline.